What Is ApoB, and Should You Get It Tested?
ApoB counts every artery-clogging particle in your blood, one apoB molecule per particle, while standard LDL-C only measures the cholesterol riding inside them. Large studies show ApoB predicts heart attacks better than LDL-C. It does not clearly beat non-HDL-C on its own, and even the guidelines admit no trial has directly tested LDL-C vs ApoB as a screening strategy.
Understand what ApoB actually measures Every atherogenic particle (LDL, VLDL, IDL, and Lp(a)) carries exactly one apoB molecule, so ApoB counts particle number directly. LDL-C only estimates the cholesterol cargo riding inside those particles.
This is the core distinction the rest of the page builds on.
See how ApoB compares to LDL-C and non-HDL-C In a 389,529-person UK Biobank study, jointly adjusting all three lipids gave ApoB a hazard ratio of 1.27 vs 1.09 for non-HDL-C. But adjusted individually, ApoB (1.38) and non-HDL-C (1.36) were nearly identical; the authors themselves flagged the joint model's collinearity as high (VIF above 10).
ApoB clearly beats LDL-C. It does not clearly beat non-HDL-C, and the honest reading of the same study shows why.
See what the guideline admits it does not know The 2019 ESC/EAS guideline's own 'Gaps in the evidence' section states no outcome-based comparison of LDL-C vs ApoB exists for screening, diagnosis and management. The ESC recommendation to measure ApoB is Class I but Level C, expert consensus, not trial evidence.
A guideline recommending a test is not the same as a trial proving the test changes outcomes.
Understand why the two numbers can disagree Around 20% of people show discordance between measured LDL-C and ApoB levels (ESC/EAS 2019, verbatim). At a fixed LDL-C of 100 mg/dL, 95% of people range from ApoB 66 to 99 mg/dL.
Discordance is the practical reason to know your own ApoB rather than assume it tracks your LDL-C.
Separate a lab's normal range from a clinical target US lab reference ranges (roughly 60 to 133 mg/dL) describe the general population, including people who go on to have heart attacks. Treatment thresholds are stricter and depend on individual risk, a conversation for a physician, not a number to self-target.
'Normal' on a lab report and 'optimal' for your risk are not the same number.
Check whether ApoB is worth asking for Fasting is not required (post-meal chylomicron particles are under 1% of circulating ApoB). The assay is standardized and inexpensive to run, but it is usually ordered separately from a routine lipid panel, and insurers sometimes deny or require prior authorization for it.
Cheap to run is not the same as automatically ordered or automatically covered.
Every atherogenic particle, LDL, VLDL, IDL and Lp(a), carries exactly one apoB molecule, so ApoB counts particle number directly instead of estimating it.
View sources
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
Association of Apolipoprotein B With Cardiovascular Risk (Marston et al., JAMA Cardiology, 2022)
Lipoprotein Discordance at a Given LDL-C (Sayed et al., JAMA Cardiology, 2024)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone who has heard 'ApoB is better than LDL' and wants the honest version
- People deciding whether to ask a doctor to add ApoB to their next panel
- Anyone comparing ApoB and non-HDL-C results that seem to disagree
Cautions
- This page is educational only: it gives no personal target number and is not a substitute for a physician's interpretation of your own results
- ApoB beats LDL-C, but it does not clearly beat non-HDL-C once lipids are adjusted individually, that nuance is easy to lose in headline summaries
- Genetic studies linking ApoB to heart disease cannot fully separate ApoB's effect from the cholesterol it carries, so 'linked to' is the accurate phrase, not 'causes'
- Lowering ApoB is usually a prescription decision (statins, ezetimibe, PCSK9 inhibitors, and similar) made with a clinician based on your individual risk, not a self-directed change